The TV ad will run through Nov. 16 across major cable channels, including CNN, Fox News and ESPN, a BMS spokesperson told ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Katie Swicegood Fulp is a bit of a late arrival to the world of pharma marketing. | In a Q&A for Fierce Pharma Marketing’s ...